Department of Medical Oncology, Queen Elizabeth Hospital, Woodville, South Australia, Australia.
Adelaide Medical School, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, South Australia, Australia.
Australas J Dermatol. 2022 Aug;63(3):e222-e225. doi: 10.1111/ajd.13881. Epub 2022 Jun 6.
Merkel cell carcinoma (MCC) is a rare and aggressive cutaneous tumour of neuroendocrine cell origin, which can grow rapidly and metastasise early. Localised disease is treated with surgery and radiotherapy. Disease that reaches a more advanced stage can be treated with a variety of different treatment modalities including surgery, radiotherapy, chemotherapy, radionuclide therapy, immunotherapy, and intralesional therapy. We report a case of a patient who had exhausted all local and systemic treatment options and who subsequently had an exceptional response to intralesional injection of Talimogene laherparepvec (TVEC).
默克尔细胞癌（Merkel cell carcinoma，MCC）是一种罕见且侵袭性强的皮肤神经内分泌细胞来源肿瘤，其生长迅速且早期转移。局限性疾病采用手术和放疗治疗。更晚期的疾病可以采用多种不同的治疗方式，包括手术、放疗、化疗、放射性核素治疗、免疫治疗和瘤内治疗。我们报告了一例患者，其已用尽所有局部和全身治疗方案，随后对瘤内注射替莫唑胺拉帕霉素（talimogene laherparepvec，TVEC）产生了极好的反应。
